Related Experiment Video
Updated: Jul 16, 2026
07:56
Scanning Skeletal Remains for Bone Mineral Density in Forensic Contexts
Published on: January 29, 2018
Polymorphisms in the CYP19 gene that influence bone mineral density
1University of Cantabria, Department of Internal Medicine, Hospital U.M. Valdecilla, Av Valdecilla sn, 39008 Santander, Spain. rianchoj@unican.es
Pharmacogenomics
|March 30, 2007
Summary
Aromatase gene variants influence bone density and fracture risk in osteoporosis. Understanding these genetic factors may aid in preventing and managing this common bone disease.
Area of Science:
- Endocrinology
- Genetics
- Bone Biology
Background:
- Osteoporosis is a common bone disease with significant genetic influence.
- Estrogens are crucial for bone homeostasis, with aromatase mediating estrogen production from androgens.
- Aromatase is therefore a key candidate gene for osteoporosis research.
Purpose of the Study:
- To review the influence of aromatase activity and gene variants on skeletal homeostasis.
- To describe associations between aromatase gene polymorphisms and bone mineral density or fracture risk.
- To discuss the implications of these genetic findings for osteoporosis prevention and management.
Main Methods:
- Literature review of studies on aromatase activity and gene variants in relation to bone health.
- Analysis of research associating common aromatase gene polymorphisms with bone mineral density (BMD).
- Examination of studies linking aromatase gene variations to the risk of osteoporotic fractures.
Main Results:
- Common polymorphisms in the aromatase gene have been studied for their association with bone mineral density.
- Evidence suggests a link between certain aromatase gene variants and the risk of osteoporotic fractures.
- Aromatase activity significantly impacts skeletal homeostasis.
Conclusions:
- Aromatase gene variants are associated with variations in bone mineral density and fracture risk.
- Genetic data related to aromatase may offer potential for personalized osteoporosis prevention and treatment strategies.
- Further research into aromatase genetics can enhance our understanding and management of osteoporosis.
Related Concept Videos
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Bone Disorders
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
01:27Principles of Pharmacogenetics: Types of Genetic Variants
The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:16Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...